Stay updated on Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial
Sign up to get notified when there's something new on the Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial page.

Latest updates to the Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial page
- Check4 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the detailed study information and related documents with an error screen. This change blocks the ability to view core study details and attachments on the page.SummaryDifference18%

- Check11 days agoChange DetectedThe page revision was updated from v3.6.6 to v3.7.0, indicating a new revision of the page content.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6, indicating a small update to the page documentation/metadata rather than substantive content.SummaryDifference0.0%

- Check32 days agoChange DetectedAdded a funding attribution entry: '2015 ( U.S. NIH Grant/Contract )' under the study's external identifiers, indicating NIH support for this trial.SummaryDifference0.0%

- Check46 days agoChange DetectedThe page’s revision label was updated from v3.6.4 to v3.6.5, indicating a software version update that changes internal metadata without altering study details or visible content.SummaryDifference0.0%

- Check67 days agoChange DetectedThe page revision metadata was updated from v3.6.3 to v3.6.4, indicating an internal update to the page. The visible study details and layout appear unchanged.SummaryDifference0.0%

Stay in the know with updates to Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ofatumumab vs Teriflunomide in Relapsing MS Clinical Trial page.